Virtu Financial’s Scinai Immunotherapeutics SCNI Stock Holding History

Virtu Financial’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5K	Buy	+1,949	New	+$9.58K	﹤0.01%	1486
2026 Q1	–	Sell	-1,541	Closed	-$11K	–	2223
2025 Q4	$11K	Buy	+1,541	New	+$17.6K	﹤0.01%	1502
2023 Q2	–	Sell	-105	Closed	-$23K	–	1972
2023 Q1	$23K	Buy	+105	New	+$25.9K	﹤0.01%	1224
2021 Q4	–	Sell	-22	Closed	-$49K	–	2123
2021 Q3	$49K	Buy	+22	New	+$56.5K	﹤0.01%	1278
2021 Q2	–	Sell	-18	Closed	-$70K	–	2007
2021 Q1	$70K	Buy	+18	New	+$78.6K	0.01%	1388
2020 Q3	–	Sell	-11	Closed	-$260K	–	1454
2020 Q2	$260K	Buy	+11	New	+$177K	0.03%	617

Other funds holding SCNI

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtu Financial's SCNI Position: Q2 2026 in Review

Virtu Financial opened a new position in Scinai Immunotherapeutics (SCNI) in Q2 2026: 1,949 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #1486 among its holdings. This is a return to the name: Virtu Financial previously reported a position in SCNI as recently as Q4 2025.

Virtu Financial first reported a position in SCNI in Q2 2020 and has held it in 6 quarters since. The position peaked at $260K in Q2 2020. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.

Virtu Financial held 1,949 shares of Scinai Immunotherapeutics worth $5K as of Q2 2026.
Scinai Immunotherapeutics was a new Virtu Financial position in Q2 2026.
Scinai Immunotherapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1486 holding.
Virtu Financial first reported a position in Scinai Immunotherapeutics in Q2 2020 and has held it in 6 quarters since.
Virtu Financial's Scinai Immunotherapeutics position peaked at $260K in Q2 2020.
11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.